NAD+ and Ageing: What Randomised Clinical Trials Actually Show

Randomised, placebo-controlled trials of NAD+ precursors have produced measurable biochemical changes. Here is what the clinical evidence indicates, and how physician-supervised NAD+ protocols work in Dubai.

By UAE Peptide Clinic Medical Team

Nicotinamide adenine dinucleotide, or NAD+, is a coenzyme present in every cell in the body. It sits at the centre of energy metabolism, transferring electrons in the reactions that generate ATP, and it acts as a required substrate for two families of repair and signalling enzymes: the sirtuins and the PARPs. Research has explored NAD+ extensively because tissue levels appear to decline substantially with age, with some studies reporting reductions approaching 50 percent by middle age.

What the randomised trials show

The most frequently cited human data comes from a 2023 randomised, multicentre, double-blind, placebo-controlled clinical trial of NMN supplementation in 80 healthy middle-aged adults (DOI: 10.1007/s11357-022-00705-1). Blood NAD+ concentrations rose significantly by day 60 relative to placebo, with dose-dependent effects across the treatment arms. Importantly, this trial demonstrated that an oral precursor can raise a measurable biomarker. It did not establish a longevity outcome, and the authors framed the findings accordingly.

A 2024 double-blind trial conducted at the University of Rhode Island (DOI: 10.1093/geroni/igaf122.3517) explored NAD+ precursor supplementation in relation to cognitive outcomes in older adults. Studies of this kind are still small and exploratory. Clinical evidence indicates biochemical engagement of the pathway; it does not yet indicate a reliable clinical endpoint.

The pathways under investigation

• Sirtuin activity: sirtuins are NAD+-dependent enzymes involved in deacetylation, metabolic regulation and stress response.
• Mitochondrial biogenesis: preclinical studies suggest NAD+ availability influences the signalling that governs mitochondrial turnover.
• DNA repair: PARP enzymes consume NAD+ when responding to DNA strand breaks, which links repair demand to cofactor availability.
• Circadian and metabolic coupling: research has examined how NAD+ oscillation interacts with metabolic rhythm.

IV versus subcutaneous administration

In Dubai, NAD+ is commonly associated with intravenous infusions. Intravenous administration delivers the molecule directly into circulation, but it requires clinic attendance and is frequently associated with transient discomfort at higher infusion rates, which is why careful physician titration matters. Subcutaneous administration is considerably more convenient for at-home use within a physician-supervised protocol, and allows more frequent, lower-dose exposure. Neither route has been established as superior in a head-to-head randomised trial; the choice is practical and clinical rather than evidence-driven.

Combination protocols

Physicians sometimes consider pairing NAD+ with MOTS-C, a mitochondrial-derived peptide that studies have examined in relation to AMPK signalling and metabolic regulation. The rationale is complementary: one supports cofactor availability, the other has been studied in relation to metabolic stress response. This remains a reasoned clinical hypothesis rather than a validated combination, and should only be undertaken with monitoring.

Physician-supervised NAD+ protocols in the UAE

At UAE Peptide Clinic, NAD+ is prescription-only and follows the same clinical pathway as every other protocol: structured intake, consultation with a DHA-registered physician, prescription where appropriate, pharmaceutical-grade dispensing, and cold-chain delivery from Dubai across the UAE. Baseline bloodwork is often requested, and protocols are reviewed rather than repeated indefinitely.

• Screening for contraindications before any protocol begins.
• Dose titration to tolerability rather than fixed high-dose exposure.
• Cold-chain delivery to Dubai, Abu Dhabi, Sharjah, Ajman, Fujairah, Ras Al Khaimah and Umm Al Quwain.
• Scheduled physician review with the option to adjust or stop.

A measured conclusion

NAD+ is one of the few longevity-adjacent interventions with genuine randomised human data behind the biomarker it targets. That is meaningful, and it is also limited. Research is ongoing, individual responses vary, and physician assessment is required before starting. Anyone promising an anti-ageing outcome is going beyond what the evidence supports.

Explore physician-supervised NAD+ protocols available in Dubai and across the UAE. View NAD+ Protocol